Objective To observe the therapeutic response and safety of rituximab in patients with anti-SRP antibody positive immune-mediated necrotizing myositis.Methods We identified five patients with anti-SRP antibody positive immune-mediated necrotizing myositis who received rituximab treatment in the rheumatology and immunology department of China-Japan Friendship Hospital from March 2022 to October 2023,and reviewed their clinical characteristics,treatment response to rituximab and adverse reaction.Results After 6 months of treatment with rituximab,3 of 5 patients were effective and all were significantly effective,1 patient showed no response,1 patient died of"pulmonary infection"after 5 months of treatment,and 1 patient developed latent tuberculosis infection.Conclusion Rituximab is effective in the treatment of anti-SRP antibody positive immune-mediated necrotizing myositis,with a low incidence of adverse reactions and overall benefits outweighing risks.
MyositisAnti signal recognition-particle autoantibodyRituximab
万方数据
